
Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-616-7660
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Basal Cell Carcinoma, Clinical Trials, Immunotherapy, Medical Oncology, Melanoma, Merkel Cell Carcinoma, Skin Cancer
Education and Experience
Training
- Mount Sinai School of Medicine (New York NY)/ (2005)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Medicine (2008)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology Center (2011)
Certifications
- Medical Oncology, American Board of Internal Medicine (2010)
- Internal Medicine, American Board of Internal Medicine (2008)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Weinberg Building
Baltimore, MD 21231
Phone: 410-955-8893
Appointment Phone: 410-616-7660
Fax: 410-955-8587
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Evan J. Lipson, M.D., is a melanoma specialist at the Johns Hopkins Kimmel Cancer Center. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipson is also the founder of SeizeTheDays.org, which chronicles the stories of cancer patients who, with power and determination, find interesting and meaningful ways to add life to their days.
Expertise
- Basal Cell Carcinoma
- Clinical Trials
- Immunotherapy
- Medical Oncology
- Melanoma
- Merkel Cell Carcinoma
- Skin Cancer
Research
Research and Publications
Evan J. Lipson, M.D., is a melanoma specialist at the Johns Hopkins Kimmel Cancer Center. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipsons concentration is in optimizing combinations of immune-based therapies, such as cancer vaccines and immune checkpoint inhibitors, in order to achieve maximal anti-tumor activity. As a part of the Melanoma and Immunotherapy programs, Dr. Lipson also collaborates with basic and translational scientists in order to investigate biomarkers of drug efficacy.
Dr. Lipson is also the founder of SeizeTheDays.org, a non-profit organization which chronicles the stories of cancer patients who, with spirit and determination, find interesting and meaningful ways to add life to their days.
1: Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011 Nov 15;17(22):6958-62. Epub 2011 Sep 7. PubMed PMID: 21900389.
2: Goyal J, Lipson EJ, Rezaee N, Edil BH, Schulick R, Wolfgang CL, Hruban RH, Antonarakis ES. Surgical Resection of Malignant Melanoma Metastatic to the
Pancreas: Case Series and Review of Literature. J Gastrointest Cancer. 2011 Sep 13. [Epub ahead of print] PubMed PMID: 21912850.
3: Lipson EJ. Art in oncology: how patients add life to their days. J Clin Oncol. 2011 Apr 1;29(10):1392-3. Epub 2011 Feb 7. PubMed PMID: 21300935.
4: Lipson EJ, Taube JM, Chen L, Topalian SL. Anti-PD-1 and anti-B7-H1/PD-L1 monoclonal antibody therapies. In: Targeted Therapeutics in Melanoma, Gajewski TF and Hodi FS (eds). New York: Humana Press. 2011.
5: Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM. Lenalidomide-induced acute interstitial nephritis. Oncologist. 2010;15(9):961-4. Epub 2010 Aug 13. PubMed PMID: 20709889.
6: Lipson EJ, Fiel MI, Florman SS, Korenblat KM. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant. 2005
Aug;19(4):487-91. PubMed PMID: 16008593.
Dr. Lipson is also the founder of SeizeTheDays.org, a non-profit organization which chronicles the stories of cancer patients who, with spirit and determination, find interesting and meaningful ways to add life to their days.
1: Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011 Nov 15;17(22):6958-62. Epub 2011 Sep 7. PubMed PMID: 21900389.
2: Goyal J, Lipson EJ, Rezaee N, Edil BH, Schulick R, Wolfgang CL, Hruban RH, Antonarakis ES. Surgical Resection of Malignant Melanoma Metastatic to the
Pancreas: Case Series and Review of Literature. J Gastrointest Cancer. 2011 Sep 13. [Epub ahead of print] PubMed PMID: 21912850.
3: Lipson EJ. Art in oncology: how patients add life to their days. J Clin Oncol. 2011 Apr 1;29(10):1392-3. Epub 2011 Feb 7. PubMed PMID: 21300935.
4: Lipson EJ, Taube JM, Chen L, Topalian SL. Anti-PD-1 and anti-B7-H1/PD-L1 monoclonal antibody therapies. In: Targeted Therapeutics in Melanoma, Gajewski TF and Hodi FS (eds). New York: Humana Press. 2011.
5: Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM. Lenalidomide-induced acute interstitial nephritis. Oncologist. 2010;15(9):961-4. Epub 2010 Aug 13. PubMed PMID: 20709889.
6: Lipson EJ, Fiel MI, Florman SS, Korenblat KM. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant. 2005
Aug;19(4):487-91. PubMed PMID: 16008593.
Research Interests
- Immunotherapy
- Melanoma
More Info
Languages
- English

